While I don't buy into the boundless pessimism of Dhukka and some others, I do think it is now incumbent on management to tell us just what is going on, especially with the cellulite cream.
What you call "boundless pessimism" I call healthy skepticism. I couldn't be that pessimistic since I've owned the stock on two separate occasions in the past 3 years. I sold out in January based on a scenario that has largely played out with the share price having fallen by about a third.
I understand people who own this stock for the 'fat tail' event, e.g. a deal with up fronts with the likes of CSL or Novartis. However, investing on the basis that the company will be self-funding inside 12 months in the absence of such a deal is pure speculation not based on any tangible evidence.
I invest in biotech, and I assume others do as well, because of the huge potential upside of a blockbuster product and or drug, but you also owe it to yourself to consider the risks.
As jevalent stated, AOD has a disappointing history, there is also precedent of disappointing outcomes related to partnerships, does anyone remember the "potential" of the Nestle partnership?
POH Price at posting:
10.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)